Dexcom officer proposes sale of 2,565 shares
The listed shares are identified as restricted stock acquired from Dexcom on March 8, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Dexcom officer Sadie Stern gave notice of a proposed sale of 2,565 common shares, with an aggregate market value of $220,974.75 and an approximate sale date of September 28, 2026. Morgan Stanley Smith Barney LLC is listed as the broker. The shares are identified as restricted stock acquired from Dexcom on March 8, 2024. The notice also reports Stern sold 2,565 common shares on August 27, 2026, with an aggregate market value of $226,669.05.
Key Figures
Key Terms
Restricted Stock financial
Rule 144 regulatory
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.